These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 7776449)

  • 1. Cytoreductive surgery for stage IV renal cell carcinoma.
    Bennett RT; Lerner SE; Taub HC; Dutcher JP; Fleischmann J
    J Urol; 1995 Jul; 154(1):32-4. PubMed ID: 7776449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection.
    Pantuck AJ; Zisman A; Dorey F; Chao DH; Han KR; Said J; Gitlitz BJ; Figlin RA; Belldegrun AS
    J Urol; 2003 Jun; 169(6):2076-83. PubMed ID: 12771723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience.
    Kassouf W; Sanchez-Ortiz R; Tamboli P; Jonasch E; Merchant MM; Spiess PE; Wood CG
    Urology; 2007 May; 69(5):835-8. PubMed ID: 17482917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
    Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
    Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
    Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
    J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma.
    Levy DA; Swanson DA; Slaton JW; Ellerhorst J; Dinney CP
    J Urol; 1998 Apr; 159(4):1168-73. PubMed ID: 9507824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma.
    Hong SK; Kwak C; Lee SE
    Urology; 2005 Sep; 66(3):518-22. PubMed ID: 16140069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy.
    Itano NB; Blute ML; Spotts B; Zincke H
    J Urol; 2000 Aug; 164(2):322-5. PubMed ID: 10893575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma.
    Ward JF; Blute ML; Cheville JC; Lohse CM; Weaver AL; Zincke H
    J Urol; 2002 Jul; 168(1):56-60. PubMed ID: 12050492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance.
    Shuch B; La Rochelle JC; Wu J; Klatte T; Riggs SB; Kabbinavar F; Belldegrun AS; Pantuck AJ
    Cancer; 2008 Sep; 113(6):1324-31. PubMed ID: 18661529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Transabdominal radical nephrectomy for renal cell carcinoma: an experience on 155 patients].
    Chen XF; Zhou FJ; Han H; Qin ZK; Liu ZW; Yu SL; Li YH; Wang H; Hou GL
    Ai Zheng; 2007 May; 26(5):528-32. PubMed ID: 17672946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Surgical treatment of perplexing renal cell carcinoma].
    Lin Z; Chen S; Ye C
    Zhonghua Zhong Liu Za Zhi; 1998 Nov; 20(6):463-4. PubMed ID: 10920947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical treatment of metastatic renal cell carcinoma.
    Tobisu K; Kakizoe T; Takai K; Tanaka Y; Mizutani T
    Jpn J Clin Oncol; 1990 Sep; 20(3):263-7. PubMed ID: 2255101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal cell carcinoma with renal vein and inferior vena caval involvement: clinicopathological features, surgical techniques and outcomes.
    Parekh DJ; Cookson MS; Chapman W; Harrell F; Wells N; Chang SS; Smith JA
    J Urol; 2005 Jun; 173(6):1897-902. PubMed ID: 15879771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma.
    Levy DA; Slaton JW; Swanson DA; Dinney CP
    J Urol; 1998 Apr; 159(4):1163-7. PubMed ID: 9507823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible?
    O'Malley RL; Brewer KA; Hayn MH; Kim HL; Underwood W; Pili R; Schwaab T
    Urology; 2011 Sep; 78(3):595-600. PubMed ID: 21777963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laparoscopic versus open cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Rabets JC; Kaouk J; Fergany A; Finelli A; Gill IS; Novick AC
    Urology; 2004 Nov; 64(5):930-4. PubMed ID: 15533480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma following nephrectomy.
    Boorjian SA; Crispen PL; Lohse CM; Leibovich BC; Blute ML
    J Urol; 2008 Jul; 180(1):99-103; discussion 103. PubMed ID: 18485415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Late" regressions of metastases from renal cancer after a period of disease progression continuing the same intermittent low dose immunotherapy regimen.
    Giacosa R; Santi R; Vaglio A; Pavone L; Ferrozzi F; Passalacqua R; Buzio C
    Acta Biomed; 2004 Aug; 75(2):126-30. PubMed ID: 15481703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.